Business Wire

“Travel and tourism builds diversified and resilient economies”: Saudi Arabia Minister of Tourism, His Excellency Ahmed Al-Khateeb, tells World Economic Forum Annual Meeting in Davos

Share

Official Travel & Tourism sessions were prominently featured on the WEF agenda, with global leaders unpacking the transformative power of the sector. His Excellency urged global leaders to give the sector the attention it deserves to catalyze sustainable, cross-border, multi-sector economic growth.

The Travel and Tourism sector’s essential contribution to shaping the global landscape was underscored at the World Economic Forum (WEF) Annual Meeting in Davos this week with His Excellency Ahmed A. Al-Khateeb, Saudi Arabia Minister of Tourism, urging world leaders to provide the industry with the focus and collaborative solutions it deserves.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124536028/en/

Saudi Minister of Tourism, His Excellency Ahmed A. Al-Khateeb put travel and tourism on the global agenda at the World Economic Forum Annual Meeting in Davos, Switzerland, this week. (Photo: AETOSWire)

Saudi Arabia welcomed nearly 30 million international visitors in 2024 and contributed almost 5% to the Kingdom’s GDP. In dedicated WEF sessions on travel and tourism, His Excellency, who attended Davos as part of the official Saudi Arabia WEF Delegation, highlighted the Kingdom’s unprecedented growth rates. He stressed the critical role that tourism has in building diversified and resilient economies, emphasizing that when Saudi Vision 2030 unlocked the travel and tourism sector, the Kingdom began building a holistic tourism experience based on international collaboration, best practices, and sustainable development.

As the WEF Annual Meeting concluded, His Excellency noted that the world was watching the remarkable resurgence of tourism, with the industry now fully recovered to pre-pandemic levels with 1.4 billion international arrivals in 2024.

“The world is counting on us to build a vibrant tourism ecosystem that meets growing demand while safeguarding our planet and quality of life. Tourism is more than an industry - it is a transformative force. We need to foster collective action to balance economic growth in the industry with social and environmental responsibility and ensuring the sector's resilience,” His Excellency said.

Throughout the forum, His Excellency led discussions as a key voice on official WEF panels including "Travel and Tourism’s Role in Building Trust” and "The Way We Will Travel”, focused on mobilizing diversified sector growth and enhancing global collaboration to propel the travel and tourism sector to keep up with growing demand, as well as a high-level session at Saudi House that explored “Scaling Sustainable Tourism: Connecting People and Places.”

He shared the stage with distinguished leaders, including Albania Prime Minister Edi Rama, European Commissioner for Transport and Tourism Apostolos Tzitzikostas, Switzerland Tourism CEO Martin Nydegger and Trip.com CEO Jane Sun who all shared His Excellency’s sentiment on the need for further global collaboration.

In alignment with Saudi Arabia’s forward-thinking tourism strategy, the Ministry launched a new investment guide, the "Hospitality Investor White Paper" during the WEF Annual Meeting. This initiative supports Vision 2030's ambitious targets, aiming to attract more than SAR 40 billion (USD 11 billion) in private investments, contribute SAR 16 billion (USD 4 billion) to the GDP, and create 1.6 million jobs by 2030.

Minister Al-Khateeb also contributed expert insights to the WEF’s "The Future of Travel and Tourism: Embracing Sustainable and Inclusive Growth” briefing paper highlighting the growing demand for sustainable travel and the importance of cross-sector collaboration and the need to ensure local communities globally benefit from the resulting growth.

As the WEF Annual Meeting concludes, Minister Al-Khateeb's participation underscores Saudi Arabia's transformative role in reshaping the global tourism landscape, reinforcing the Kingdom's vision to establish itself as a leading hub for sustainable travel.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124536028/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye